RemeGen launches $514m Hong Kong listing
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings
Asia

RemeGen launches $514m Hong Kong listing

Jonathan Breen
October 28, 2020 05:45 AM
biopharma_stocks_adobe_575x375.jpg

RemeGen, a Chinese biopharmaceutical company, has rolled out a Hong Kong IPO that could be worth up to HK$3.99bn ($514.5m).

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP MorganEquity IPOsHealth and BiotechUBSEquityChinaHong Kong SARAsiaGreater ChinaBank of CommunicationsHaitong SecuritiesMorgan StanleyNortheast AsiaAsia PacificEmerging MarketsSRI
JB
Jonathan Breen
Equities editor GlobalCapital Asia
Contact
Gift this article